Recent gene therapy advancements for neurological diseases.
Authors:
- Sahana Nagabhushan KalburgiSKSahana Nagabhushan Kalburgi
- Nadia N KhanNKNadia N Khan
- Steven J GraySGSteven J Gray
- 1 February 2013
- journal article
- review article
- Vol. 15 (81) , 111-9
Abstract
The past few years have seen rapid advancements in vector-mediated gene transfer to the nervous system and modest successes in human gene therapy trials. The purpose of this review is to describe commonly-used viral gene transfer vectors and recent advancements towards producing meaningful gene-based treatments for central nervous system (CNS) disorders. Gene therapy trials for Canavan disease, Batten disease, adrenoleukodystrophy, and Parkinson's disease are discussed to illustrate the current state of clinical gene transfer to the CNS. Preclinical studies are under way for a number of diseases, primarily lysosomal storage disorders, using a newer generation of vectors and delivery strategies. Relevant studies in animal models are highlighted for Mucopolysaccharidosis IIIB and Krabbe disease to provide a prelude for what can be expected in the coming years for human gene transfer trials, using recent advancements in gene transfer technology. In conclusion, recent improvements in CNS gene transfer technology are expected to significantly increase the degree of disease rescue in future CNS-directed clinical trials, exceeding the modest clinical successes that have been observed so far.Keywords
This publication has 95 references indexed in Scilit:
- Preclinical Differences of Intravascular AAV9 Delivery to Neurons and Glia: A Comparative Study of Adult Mice and Nonhuman PrimatesMolecular Therapy, 2011
- Correction of Neurological Disease of Mucopolysaccharidosis IIIB in Adult Mice by rAAV9 Trans-Blood–Brain Barrier Gene DeliveryMolecular Therapy, 2011
- Engineering Liver-detargeted AAV9 Vectors for Cardiac and Musculoskeletal Gene TransferMolecular Therapy, 2011
- Directed Evolution of a Novel Adeno-associated Virus (AAV) Vector That Crosses the Seizure-compromised Blood–Brain Barrier (BBB)Molecular Therapy, 2010
- LEDGF Hybrids Efficiently Retarget Lentiviral Integration Into HeterochromatinMolecular Therapy, 2010
- Lentiviral Vectors in Gene Therapy: Their Current Status and Future PotentialArchivum Immunologiae et Therapiae Experimentalis, 2010
- Evidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome ≥8.2 kbMolecular Therapy, 2010
- Effect of Genome Size on AAV Vector PackagingMolecular Therapy, 2010
- Intravenous Administration of Self-complementary AAV9 Enables Transgene Delivery to Adult Motor NeuronsMolecular Therapy, 2009
- Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBMMolecular Therapy, 2009